Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
Fifteen patients with therapy-resistant liver metastases were treated in a phase-I study with recombinant human TNF (rTNF). The rTNF was injected into one liver metastasis by ultrasound guidance, using a 50 microgram escalating dose schedule (3 patients/dosage) ranging from 100-350 micrograms/injection. Influenza-like symptoms like fever, chills, nausea and vomiting were the main clinical side effects. Two patients, treated concomitantly with rTNF and morphine, showed mild hypotension. Other toxicities, as reported after systemic use of rTNF, such as decrease in leukocyte and platelet counts, renal or liver toxicity were not observed. In eight patients growth arrest was observed in rTNF-treated metastases, whereas non-injected lesions showed growth progression. The maximum tolerated dose by this route of administration is greater than 350 micrograms/injection. Based on these observations it is concluded that the toxicity of rTNF injected into liver metastases by sonographic control is transient and mild and that intratumoural administration of rTNF might play a role in local tumour control.
IJzermans
J N
JN
Department of Surgery, Academic Hospital Rotterdam Dijkzigt, Erasmus University, The Netherlands.
van der Schelling
G P
GP
Scheringa
M
M
Splinter
T A
TA
Marquet
R L
RL
Jeekel
J
J
D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015552:Injections, Intralesional / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014463:Ultrasonography
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha